{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T09:41:30Z","timestamp":1789810890929,"version":"4.0.1"},"reference-count":163,"publisher":"Informa UK Limited","issue":"5","funder":[{"name":"Postdoctoral Fellowship Program of CPSF","award":["GZC20231489"],"award-info":[{"award-number":["GZC20231489"]}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2023M742101"],"award-info":[{"award-number":["2023M742101"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","award":["ZR2024QH201"],"award-info":[{"award-number":["ZR2024QH201"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Shandong Laboratory Program","award":["SYS202205"],"award-info":[{"award-number":["SYS202205"]}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Therapeutic Patents"],"published-print":{"date-parts":[[2025,5,4]]},"DOI":"10.1080\/13543776.2025.2467699","type":"journal-article","created":{"date-parts":[[2025,2,22]],"date-time":"2025-02-22T12:57:26Z","timestamp":1740229046000},"page":"441-461","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":3,"title":["A patent review of hepatitis B virus core protein allosteric modulators (2019-present)"],"prefix":"10.1080","volume":"35","author":[{"given":"Shuo","family":"Wang","sequence":"first","affiliation":[{"name":"Shandong University","place":["Jinan, PR China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feiyue","family":"Ma","sequence":"additional","affiliation":[{"name":"Shandong University","place":["Jinan, PR China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Tang","sequence":"additional","affiliation":[{"name":"Shandong University","place":["Jinan, PR China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shujing","family":"Xu","sequence":"additional","affiliation":[{"name":"Shandong University","place":["Jinan, PR China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyong","family":"Jia","sequence":"additional","affiliation":[{"name":"Shandong Second Medical University","place":["Weifang, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyong","family":"Liu","sequence":"additional","affiliation":[{"name":"Shandong University","place":["Jinan, PR China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Zhan","sequence":"additional","affiliation":[{"name":"Shandong University","place":["Jinan, PR China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2025,3,6]]},"reference":[{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v13.i1.14"},{"key":"e_1_3_4_4_1","unstructured":"World Health Organization. Global hepatitis report 2024: action for access in low- and middle-income countries 2024. Geneva Switzerland; 2024."},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.coviro.2021.04.009"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(22)00124-8"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2020.112714"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2023.103617"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2017.11.015"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbpa.2019.02.009"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2016.08.004"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cclet.2023.108349"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2020.104917"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1021\/acschembio.0c00320"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11051349"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2018.12.023"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1080\/17460441.2023.2239701"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2022.105485"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.3390\/v15051195"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2023.105715"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2021.113780"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1039\/D3MD00461A"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2022.106192"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.4c01814"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.4c01568"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.3390\/molecules26247420"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01686-19"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00044-022-02936-5"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00044-023-03095-x"},{"key":"e_1_3_4_30_1","unstructured":"Wan ZK Jiang YM Dai XD et al. Heteroaryldihydropyrimidine derivatives and methods of treating hepatitis b infections. WO2019001420A1. 2018."},{"key":"e_1_3_4_31_1","unstructured":"Qiu YL Gao XR Peng XW et al. Hepatitis b antiviral agents. WO2019113173. 2018."},{"key":"e_1_3_4_32_1","unstructured":"Qiu YL Peng XW Kass J et al. Hepatitis b antiviral agents. WO2019113175. 2018."},{"key":"e_1_3_4_33_1","unstructured":"Jiang YM Wan ZK Cheung WS et al. Dihydropyrimidine derivatives and uses thereof in the treatment of hbv infection or of hbv-induced diseases. WO2019214610A1. 2019."},{"key":"e_1_3_4_34_1","unstructured":"Deng G Jiang YM Liu Q et al. Dihydropyrimidine derivatives and uses thereof in the treatment of hbv infection or of hbv-induced diseases. WO2020001448. 2019."},{"key":"e_1_3_4_35_1","unstructured":"Qiu YL Peng XW Li W et al. Hepatitis b antiviral agents. WO2020247575. 2020."},{"key":"e_1_3_4_36_1","unstructured":"Deng G Cheng ZL Liu ZG et al. Heteroaryldihydropyrimidine derivatives and methods of treating hepatitis b infections. WO2021121363A1. 2020."},{"key":"e_1_3_4_37_1","unstructured":"Zhan P Ma Y Liu XY et al. Dihydropyrimidine-spiro derivative and preparation method and application thereof. CN113135921A. 2021."},{"key":"e_1_3_4_38_1","unstructured":"Ren QY Liu XC Zhang YJ et al. Dihydropyrimidine compound and application thereof in medicine. CN113831359A. 2021."},{"key":"e_1_3_4_39_1","unstructured":"Hu YH Li X Kong DS et al. Dihydropyrimidine compound and application thereof. WO2022052923A1. 2021."},{"key":"e_1_3_4_40_1","unstructured":"Jiang YM Cheng ZL Deng G et al. Dihydropyrimidine derivatives and uses thereof in the treatment of hbv infection or of hbv-induced diseases. WO2022161448A1. 2022."},{"key":"e_1_3_4_41_1","unstructured":"Wu DD Hu YH Li X et al. Phenyldihydropyrimidine compound and use thereof. WO2022166923A1. 2022."},{"key":"e_1_3_4_42_1","unstructured":"Tang GZ Ma DW Chen JL et al. Dihydropyrimidine compound preparation method and application thereof. CN114907355A. 2022."},{"key":"e_1_3_4_43_1","unstructured":"Jiang YM Cheng ZL Deng G et al. Dihydropyrimidine derivatives and uses thereof in the treatment of hbv infection or of hbv-induced diseases. WO2022257942A1. 2022."},{"key":"e_1_3_4_44_1","unstructured":"Sha W Liu Y Li JY et al. Dihydropyrimidine derivatives and uses thereof. CN116143786A. 2022."},{"key":"e_1_3_4_45_1","unstructured":"Zhan P Zhao SJ Liu XY et al. Dihydropyrimidine derivative containing boric acid and boric acid pinacol ester group and preparation method and application thereof. CN116284080A. 2023."},{"key":"e_1_3_4_46_1","unstructured":"Li X Zhang ZG Chen LX et al. Piperazine ureido derivatives preparation method thereof and application thereof in medicines. CN112778299B. 2020."},{"key":"e_1_3_4_47_1","unstructured":"Liu XY Zhao SJ Zhan P et al. Dihydropyrimidine derivative containing carboxylic acid and preparation method and application thereof. CN116675687A. 2023."},{"key":"e_1_3_4_48_1","unstructured":"George D Hartman GD Kuduk S. Azepane derivatives and methods of treating hepatitis b infections. US2019016682A1. 2017."},{"key":"e_1_3_4_49_1","unstructured":"Yao L Qiu YL Cao H et al. Hepatitis b antiviral agents. WO2019046271A1. 2018."},{"key":"e_1_3_4_50_1","unstructured":"Ji MZ Cao QX Liu LF et al. Sulfamide aryl formamide derivative and preparation method therefor and uses thereof. WO2019206072A1. 2019."},{"key":"e_1_3_4_51_1","unstructured":"Francesco RD Donnici L Guidotti L et al. Cyclic inhibitors of hepatitis b virus. WO2020016434A1. 2019."},{"key":"e_1_3_4_52_1","unstructured":"Yang Z Wang J Li J et al. Antiviral agent for hepatitis B virus infection. CN111349056B. 2020."},{"key":"e_1_3_4_53_1","unstructured":"Yang Z Wang J Li J et al. Antiviral agent for hepatitis B virus infection. CN111393391A. 2020."},{"key":"e_1_3_4_54_1","unstructured":"Zhan P Ren YJ Liu XY et al. Benzenesulfonyl amine HBV capsid protein inhibitor containing boric acid and boric acid pinacol ester group and preparation method and application thereof. CN113801153A. 2021."},{"key":"e_1_3_4_55_1","unstructured":"Jia HY Chen YF Yan F et al. Anti-hbv sulfanilamide benzamide derivative and preparation method and application thereof. CN115677545A. 2022."},{"key":"e_1_3_4_56_1","unstructured":"Burns CJ Coburn G Liu B et al. Hepatitis b capsid assembly modulators. WO2019118358A1. 2018."},{"key":"e_1_3_4_57_1","unstructured":"Jia HY Wang M Zhan P et al. Benzamide HBV capsid protein inhibitor and preparation method and application thereof. CN116410106A. 2023."},{"key":"e_1_3_4_58_1","unstructured":"Gu GY Dan YJ Jint SP et al. Anti-HBV agent. WO2024029481A1. 2023."},{"key":"e_1_3_4_59_1","unstructured":"Ly TW Chuang SC Guo JR et al. Antiviral agents. US20220098169A1. 2021."},{"key":"e_1_3_4_60_1","unstructured":"Ivachtchenko AV Ivashchenko AA Savchuk NF. Preparation of hybrid arylcarboxamides\/heterocyclic sulfonamides as hepatitis virus B (HBV) inhibitors. WO2019017814A1. 2019."},{"key":"e_1_3_4_61_1","unstructured":"Zhang YS Ao WW Shen HZ et al. Capsid protein assembly inhibitor and pharmaceutical composition and use thereof. WO2019154343A1. 2019."},{"key":"e_1_3_4_62_1","unstructured":"Burns CJ Coburn G Liu B et al. Hepatitis b capsid assembly modulators. WO2019118358. 2018."},{"key":"e_1_3_4_63_1","unstructured":"Guo WB Zhang DK Jin WL et al. HBV inhibitor and use thereof. WO2021093172A1. 2020."},{"key":"e_1_3_4_64_1","doi-asserted-by":"crossref","unstructured":"Bai C Gao YY Li KL. Aromatic hetero amine derivatives and preparation method and application thereof. CN113717125. 2021.","DOI":"10.1016\/j.focat.2021.10.033"},{"key":"e_1_3_4_65_1","unstructured":"Sarafianos SG Wang ZQ Huber AD et al. Inhibitors of hepatitis b virus targeting capsid assembly. US20190092742A1. 2018."},{"key":"e_1_3_4_66_1","unstructured":"Walker M Li LP Haydar SN et al. Cyclic sulfamide compounds for treatment of hbv. WO2020051319A1. 2019."},{"key":"e_1_3_4_67_1","unstructured":"Walker M Li LP Haydar SN et al. Cyclic sulfamide compounds for treatment of hbv. WO2020051320. 2019."},{"key":"e_1_3_4_68_1","unstructured":"Kesteleyn BRR Berke JM Coesemans E et al. Amide derivatives useful in the treatment of hbv infection or hbv-induced diseases. WO2020225230A1. 2020."},{"key":"e_1_3_4_69_1","unstructured":"Ruengsatra T Rattanangkool E Chaiyakunvat P et al. Pyrrolidine-3-carboxamide derivatives and related uses. WO2022087422A1. 2021."},{"key":"e_1_3_4_70_1","unstructured":"Huang LY Tang N Wang K et al. N-sulfonyl heterocyclic derivative and pharmaceutical use thereof. CN112679489B. 2020."},{"key":"e_1_3_4_71_1","unstructured":"Zhang YS Ao WW Li Y et al. N-heterocyclic five-membered ring-containing capsid protein assembly inhibitor pharmaceutical composition thereof and use thereof. WO2019185016A1. 2019."},{"key":"e_1_3_4_72_1","unstructured":"Burns CJ Coburn G Liu B et al. Hepatitis b capsid assembly modulators. US2019375708A1. 2019."},{"key":"e_1_3_4_73_1","unstructured":"Last SJ Romanie BR Grosse SC et al. Pyrrole derivatives useful in the treatment of HBV infection or hbv-induced diseases and their preparation. WO2020169784A1. 2020."},{"key":"e_1_3_4_74_1","unstructured":"Vendeville S Smith DB Beigelman L et al. Pyrrole compounds as antiviral agents for the treatment of hepatitis B and D and their preparation. WO2020205934A1. 2020."},{"key":"e_1_3_4_75_1","unstructured":"Burns CJ Coburn G Liu B et al. Pyrrole-3-carboxamides as hepatitis B capsid assembly modulators and their preparation. WO2021119081A1. 2021."},{"key":"e_1_3_4_76_1","unstructured":"Zhang YJ Liu XC Ren QY et al. Preparation of pyrimidine containing amide pyrrole derivatives and application thereof. CN114685514A. 2022."},{"key":"e_1_3_4_77_1","unstructured":"Fu SC Xu HY Nie W et al. Preparation method of polysubstituted pyrrole compounds and their application thereof. CN116120219A. 2023."},{"key":"e_1_3_4_78_1","unstructured":"Luo XF Shi YQ Xie HL et al. Pyrrolamide compound preparation method and application thereof. CN116768776A. 2023."},{"key":"e_1_3_4_79_1","unstructured":"Gutierrez DA Kobayashi TL Scott E et al. Preparation of substituted pyrrolizine derivatives as HBV replication inhibitors. WO2019165374A1. 2019."},{"key":"e_1_3_4_80_1","unstructured":"He HY Xia JH Gong Z et al. Shuhui2 3-dihydro-1H-pyrrolidine-7-carboxamide derivatives as nucleoprotein inhibitors and their preparation pharmaceutical compositions and use in the treatment of HBV related diseases. WO2019223791A1. 2019."},{"key":"e_1_3_4_81_1","unstructured":"Burns CJ Coburn G Liu B et al. Preparation of substituted pyrrolecarboxamides as hepatitis B capsid assembly modulators. WO2019241292A1. 2019."},{"key":"e_1_3_4_82_1","unstructured":"Kultgen S Cole AG. Substituted tetrahydrocyclopenta[c]pyrroles substituted dihydropyrrolizines analogues thereof and methods using same. WO2020023710A1. 2020."},{"key":"e_1_3_4_83_1","unstructured":"Zhang YS Ao WW Wang H et al. Capsid protein assembly inhibitor containing pyrrolo heterocycle. WO2020156494A1. 2020."},{"key":"e_1_3_4_84_1","unstructured":"Luo XF Luo H Xie HL et al. Preparation of pyrrolocyclic compounds for treatment and\/or prevention of HBV infection. CN117586264A. 2024."},{"key":"e_1_3_4_85_1","unstructured":"Wang Z Wang XG Yang S et al. Endocyclic thiamidinoamide-arylamide compound and use thereof for treating hepatitis B. WO2019011323A1. 2019."},{"key":"e_1_3_4_86_1","unstructured":"De Francesco R Donnici L Guidotti L et al. Preparation of arylaminocarbonyl pyrrolo-fused tricyclic sulfonamides as inhibitors of hepatitis B virus. WO2020030781A1. 2020."},{"key":"e_1_3_4_87_1","unstructured":"Beigelman L Smith DB. Bicyclic sulfonamides as antiviral agents and their preparation. WO2020167984A1. 2020."},{"key":"e_1_3_4_88_1","unstructured":"De FR Donnici L Guidotti L et al. Preparation of oxalamido-substituted tricyclic inhibitors of hepatitis B virus. WO2020234483A1. 2020."},{"key":"e_1_3_4_89_1","unstructured":"Di FR Summa V Bencheva LI et al. Preparation of spirocyclic inhibitors of hepatitis B virus. WO2021160617. 2021."},{"key":"e_1_3_4_90_1","unstructured":"Yao JC Coburn G Liu B et al. Preparation of hexahydropyrroloazepines as hepatitis B capsid assembly modulators useful as antiviral agents. WO2021178362A1. 2021."},{"key":"e_1_3_4_91_1","unstructured":"Donald A Urban A Bonsmann S et al. Preparation of novel pyrazolo-piperidine substituted indole-2-carboxamides active against the hepatitis B virus (HBV). WO2019086142A1. 2019."},{"key":"e_1_3_4_92_1","unstructured":"Donald A Urban A Bonsmann S et al. Novel urea 6 7-dihydro-4H-pyrazolo[4 3-c]pyridines as antiviral agents for treatment and prevention of hepatitis B. WO2020089452A1. 2020."},{"key":"e_1_3_4_93_1","unstructured":"Kuduk SD Grosse SC Last SJ et al. Fused heterocyclic derivatives as antiviral agents and their preparation. WO2020243153A1. 2020."},{"key":"e_1_3_4_94_1","unstructured":"Kuduk SD Deratt LG. Di-fluoro azepanes as HBV capsid assembly modulators and their preparation. WO2020239862A1. 2020."},{"key":"e_1_3_4_95_1","unstructured":"Kuduk SD. Azepines as HBV capsid assembly modulators and their preparation. WO2020239861A1. 2020."},{"key":"e_1_3_4_96_1","unstructured":"Grosse SC Deratt LG Vandyck K et al. Fused heterocyclic derivatives as antiviral agents and their preparation. WO2020243135A1. 2020."},{"key":"e_1_3_4_97_1","unstructured":"Liu LZ Deng G Lu CL et al. Preparation of fused heterocyclic compounds as HBV inhibitors. WO2022116998A1. 2022."},{"key":"e_1_3_4_98_1","unstructured":"Liu LZ Deng G Lu CL et al. Preparation of fused heterocyclic compounds as HBV inhibitors. WO2022116999. 2022."},{"key":"e_1_3_4_99_1","unstructured":"Lu CL Deng G Liu LZ et al. Fused heterocyclic derivatives their preparation method and application for treating HBV diseases. WO2022253255A1. 2022."},{"key":"e_1_3_4_100_1","unstructured":"Donald A Urban A Bonsmann S et al. Novel urea 6 7-dihydro-4H-thiazolo[5 4-c]pyridines as antiviral agents for treatment and prevention of hepatitis B. WO2020089460A1. 2020."},{"key":"e_1_3_4_101_1","unstructured":"Donald A Urban A Bonsmann S et al. Preparation of novel amino-thiazole substituted indole-2-carboxamides active against the hepatitis B virus (HBV). WO2019086141A1. 2019."},{"key":"e_1_3_4_102_1","unstructured":"Fu JP Lindvall M Manning JR et al. Preparation of novel dihydroisoxazole compounds and their use for the treatment of hepatitis B. WO2019097479A1. 2019."},{"key":"e_1_3_4_103_1","unstructured":"Kuduk S Vendeville SMH. Preparation of isoxazole compounds useful for the treatment of diseases associated with HBV infection. WO2019126622A1. 2019."},{"key":"e_1_3_4_104_1","unstructured":"Grosse SC Berke JM Hsiao M-Y et al. Preparation of fused ring pyrimidone derivatives for use in the treatment of HBV infection or of hbv-induced diseases. WO2020182990. 2020."},{"key":"e_1_3_4_105_1","unstructured":"Vendeville S Vendeville S Weil D. Preparation of tricyclic compounds useful for the treatment of HBV. US20220000874A1. 2022."},{"key":"e_1_3_4_106_1","unstructured":"Liu LZ Deng G Lu CL et al. Preparation of fused ring pyrimidone derivatives for the treatment of HBV infection or of hbv-induced diseases. WO2022053010A1. 2022."},{"key":"e_1_3_4_107_1","unstructured":"Vendeville S Debing Y Raboisson P-M. Preparation of tricyclic compounds for treatment of hepatitis B and D. WO2022115384A1. 2022."},{"key":"e_1_3_4_108_1","unstructured":"Vendeville S Smith DB Zhang Q et al. Bicyclic compounds as antiviral agents and their preparation. WO2024073559A1. 2024."},{"key":"e_1_3_4_109_1","unstructured":"Qiu Y-L Kass J Suh B-C et al. Hepatitis B antiviral agents. WO2019191166A1. 2019."},{"key":"e_1_3_4_110_1","unstructured":"Fu JP Jain R Jin XM et al. Preparation of indole-2-carbonyl compounds for the treatment of hepatitis B. WO2019166951A1. 2019."},{"key":"e_1_3_4_111_1","unstructured":"Donald A Urban A Bonsmann S et al. Preparation of 6 7-dihydro-4h-pyrazolo[1 5-a]pyrazine indole-2-carboxamides active against the hepatitis B virus (HBV. WO2020089455A1. 2020."},{"key":"e_1_3_4_112_1","unstructured":"Donald A Urban A Bonsmann S et al. Preparation of 6 7-dihydro-4h-pyrazolo[1 5-a]pyrazine indole-2-carboxamides active against the hepatitis B virus (HBV). WO2020089453A1. 2020."},{"key":"e_1_3_4_113_1","unstructured":"Donald A Urban A Bonsmann S et al. Preparation of urea 6 7-dihydro-4H-pyrazolo[1 5-a]pyrazines as antiviral agents for treatment and prevention of hepatitis B. WO2020089456A1. 2020."},{"key":"e_1_3_4_114_1","unstructured":"Donald A Urban A Bonsmann S et al. Novel urea 6 7-dihydro-4H-pyrazolo[1 5-a]pyrazines as antiviral agents for treatment and prevention of hepatitis B. WO2020089459A1. 2020."},{"key":"e_1_3_4_115_1","unstructured":"Cole AG Fan Y Kultgen S et al. Substituted arylmethylureas and heteroarylmethylureas use in treating HBV and preparation. WWO2020123674A1. 2020."},{"key":"e_1_3_4_116_1","unstructured":"Cole AG Dorsey B Fan Y et al. Substituted bicyclic and Tricyclic Ureas and Amides analogues thereof and methods using same. WO2021127356A1. 2021."},{"key":"e_1_3_4_117_1","unstructured":"Li WH Qi XB Qiu YL et al. Hepatitis B antiviral agents. WO2023169535A1. 2023."},{"key":"e_1_3_4_118_1","unstructured":"Heckrodt T Walker M Zhong M. Preparation of 5-membered heteroaryl carboxamides for the treatment of hepatitis B (HBV) viral infection. WO2023069544A1. 2023."},{"key":"e_1_3_4_119_1","unstructured":"He HY Wang J Jiang ZG et al. Preparation of the tri-cycle compound and their medical applications in the treatment of HBV related diseases. WO2018153285. 2018."},{"key":"e_1_3_4_120_1","unstructured":"Kim YC Park SG Seo J et al. Preparation of pyrimidinamine derivatives as capsid assembly inhibitors. WO2022098170A1. 2022."},{"key":"e_1_3_4_121_1","unstructured":"Hu YH Zuo JP Chen WH et al. Preparation pharmaceutical composition and use of 4-pyridine substituted phthalazinone compounds. CN112125881A. 2020."},{"key":"e_1_3_4_122_1","unstructured":"Hu YH Zuo JP Lu D et al. Preparation of phthalazinone compounds useful for the treatment of hepatitis B. CN109134429A. 2019."},{"key":"e_1_3_4_123_1","unstructured":"Sheng R Wang YW Yu YZ et al. Preparation of (pyrazolyl)oxazolidinone derivatives as anti-hbv agent. CN117466880A. 2024."},{"key":"e_1_3_4_124_1","unstructured":"Sheng R Wang Y Zhang FM. Preparation of 5-alkyl-2-pyrazole-oxazolidine-4-ketone derivatives for treating a hepatitis B disease. WO2022135601A1. 2022."},{"key":"e_1_3_4_125_1","unstructured":"Du YM Guo J-T Hwang N. Preparation of bicyclic carboxamide with exocyclic urea derivatives as antivirals for the treatment of HBV infection. US20210371388A1. 2021."},{"key":"e_1_3_4_126_1","unstructured":"Xie YH Wang X Song YY et al. Application of benzimidazole compounds in preparation of anti-hepatitis B virus drugs for inhibiting replication of virus. CN113952334B. 2022."},{"key":"e_1_3_4_127_1","unstructured":"Park S-G Kang J-A Cho Y et al. Use of ciclopirox for inhibiting HBV core assembly. WO2020040327A1. 2020."},{"key":"e_1_3_4_128_1","unstructured":"Hu JL Huang AL Wei XF. Application of 20-deoxyingenol in inhibiting HBV replication. CN110251495A. 2019."},{"key":"e_1_3_4_129_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2021.05.012"},{"key":"e_1_3_4_130_1","doi-asserted-by":"publisher","DOI":"10.1080\/17460441.2023.2294948"},{"key":"e_1_3_4_131_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-10200-5"},{"key":"e_1_3_4_132_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01302-18"},{"key":"e_1_3_4_133_1","unstructured":"Butch C Xiong YJ Wang YQ. De Novo design and virtual screening method of novel hepatitis b virus capsid assembly modulators based on generative models and computational chemistry. CN116504302B. 2023."},{"key":"e_1_3_4_134_1","doi-asserted-by":"publisher","DOI":"10.3390\/v14112404"},{"key":"e_1_3_4_135_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00082-18"},{"key":"e_1_3_4_136_1","doi-asserted-by":"publisher","DOI":"10.1038\/srep42374"},{"key":"e_1_3_4_137_1","doi-asserted-by":"publisher","DOI":"10.1039\/D1MD00318F"},{"key":"e_1_3_4_138_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2023.103581"},{"key":"e_1_3_4_139_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2019.103363"},{"key":"e_1_3_4_140_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.3c01022"},{"key":"e_1_3_4_141_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2020.115952"},{"key":"e_1_3_4_142_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2023.106923"},{"key":"e_1_3_4_143_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2023.129350"},{"key":"e_1_3_4_144_1","doi-asserted-by":"publisher","DOI":"10.3390\/molecules27185987"},{"key":"e_1_3_4_145_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2024.104115"},{"key":"e_1_3_4_146_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01558-15"},{"key":"e_1_3_4_147_1","doi-asserted-by":"publisher","DOI":"10.1021\/acsinfecdis.6b00159"},{"key":"e_1_3_4_148_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.0c00346"},{"key":"e_1_3_4_149_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2023.115485"},{"key":"e_1_3_4_150_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2020.112374"},{"key":"e_1_3_4_151_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2018.12.047"},{"key":"e_1_3_4_152_1","doi-asserted-by":"publisher","DOI":"10.1021\/acsinfecdis.8b00235"},{"key":"e_1_3_4_153_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2019.05.029"},{"key":"e_1_3_4_154_1","doi-asserted-by":"publisher","DOI":"10.3390\/v14020348"},{"key":"e_1_3_4_155_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2023.115141"},{"key":"e_1_3_4_156_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xinn.2024.100683"},{"key":"e_1_3_4_157_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.4c01347"},{"key":"e_1_3_4_158_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2020.07.017"},{"key":"e_1_3_4_159_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.4c00091"},{"key":"e_1_3_4_160_1","doi-asserted-by":"publisher","DOI":"10.15212\/AMM-2023-0019"},{"key":"e_1_3_4_161_1","doi-asserted-by":"publisher","DOI":"10.1080\/17460441.2024.2360416"},{"key":"e_1_3_4_162_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2018.11.021"},{"key":"e_1_3_4_163_1","doi-asserted-by":"publisher","DOI":"10.4155\/fmc.14.50"},{"key":"e_1_3_4_164_1","doi-asserted-by":"publisher","DOI":"10.2174\/0929867311320130011"},{"key":"e_1_3_4_165_1","doi-asserted-by":"publisher","DOI":"10.2174\/0929867311320060007"}],"container-title":["Expert Opinion on Therapeutic Patents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13543776.2025.2467699","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T11:17:41Z","timestamp":1746184661000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13543776.2025.2467699"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,6]]},"references-count":163,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5,4]]}},"alternative-id":["10.1080\/13543776.2025.2467699"],"URL":"https:\/\/doi.org\/10.1080\/13543776.2025.2467699","relation":{},"ISSN":["1354-3776","1744-7674"],"issn-type":[{"value":"1354-3776","type":"print"},{"value":"1744-7674","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,6]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ietp20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ietp20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2024-08-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-07","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}